MDGL Madrigal Corp: Price-to-Projected Revenue Ratio

Madrigal Pharmaceuticals - graphic logo of issuer MDGL

Volatility in Madrigal Pharmaceuticals (MDGL) shares is driven by a fierce battle for leadership in liver therapy. The forward P/S ratio visualizes these fluctuations, while 6.90 determines the latest valuation metric. AI-driven molecule screening and colossal demand for NASH treatment provide stability. Investors can track expected revenue dynamics, balancing potential growth against the risks of asset impairment.

Madrigal Pharmaceuticals, Inc. - MDGL Market Cap to Expected Sales Ratio (period 08/09/2024 - 11/15/2026)

Summary analytical data breakdowns for madrigalpharma.com (MDGL)

- market price and analyst price targets:
Price Chart madrigalpharma.com|MDGL - Average Forecast Price
- company stock capitalization data:
Market Value Madrigal Pharmaceuticals, Inc.|MDGL - Total Company Value
- book value of equity indicators:
Book Value per Share Madrigal Pharmaceuticals|MDGL - Book Valuation of Business|Market Value to Book Value Ratio madrigalpharma.com|MDGL - Company Total Asset Base
- business debt structure and liquidity details:
Debt to Equity Madrigal Pharmaceuticals|MDGL - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Madrigal Pharmaceuticals Inc|MDGL - Company Total Debt|Debts to Book Capitalization Madrigal Pharmaceuticals|MDGL - Company Long-Term Debts|Company Short-Term Debts Madrigal Pharmaceuticals|Quick Liquidity madrigalpharma.com
- financial results and valuation multiples details:
MDGL - Final Profit|Projected Future Earnings Madrigal Pharmaceuticals|MDGL - Business Payback Period|Forward P/E Multiple Madrigal Corp|MDGL - Price to Net Income Growth Ratio|EV/EBITDA Multiple Madrigal Pharmaceuticals|MDGL - Operating profit EBITDA|Earnings per share for the last twelve months Madrigal Pharmaceuticals|MDGL - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months madrigalpharma.com|MDGL - Earnings per share increase in current year|Net earnings per share growth forecast for next year Madrigal Pharmaceuticals
- sales volume and revenue indicators:
MDGL - Company Annual Revenue|Projected Sales Volume Madrigal Pharma|MDGL - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Madrigal Pharmaceuticals|MDGL - Sales Growth YoY (TTM)
Analysis of all company metrics:Madrigal Pharmaceuticals Inc MDGL
Original product of Madrigal Pharmaceuticals

Analyzing the forward price-to-sales chart allows for an assessment of the market status of Madrigal Pharmaceuticals (MDGL) as a biopharmaceutical issuer. This ratio correlates current market capitalization with projected annual revenue, revealing the extent to which future cash flows are overvalued. For Madrigal Pharmaceuticals (MDGL), this indicator is sensitive to geopolitical risks affecting international component logistics and patent protection, which determines the company's resilience to potential corrections.

Competitors of Madrigal Pharmaceuticals

Price-to-Projected Revenue Ratio ascendispharma.com ASND|Corcept Therapeutics Corp (CORT) - Market Cap to Future Revenue Ratio|RYTM - Price-to-Projected Revenue Ratio|AKRO: Price-to-Projected Revenue Ratio|MTSR: Forward P/S Multiple|MLTX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Crinetics Corp|NewAmsterdam Pharma Corp (NAMS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio soleno.life (SLNO)|Forward Price-to-Revenue Multiple Amicus Therapeutics FOLD|Forward Price to Sales 89bio Inc|Forward P/S Multiple Agios Pharmaceuticals, Inc. AGIO|GPCR: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio MiMedx Corp MDXG|RZLT (Rezolute Corp) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue LXRX|MBX (MBX Biosciences) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Altimmune Inc (ALT)|Forward Price-to-Revenue Multiple AARD (Aardvark Therapeutics Corp)|Forward Price-to-Revenue Multiple Sagimet SGMT|Forward P/S Multiple BIOA (BioAge Labs)|Forward P/S Multiple Biomea Fusion BMEA|QNCX: Forward Price-to-Revenue Multiple|GUTS: Price-to-Projected Revenue Ratio|vTv Therapeutics Inc (VTVT) - Price-to-Projected Revenue Ratio|ATPC: Price to Expected Revenue Ratio|PLUR (pluri-biotech.com) - Forward P/S Multiple|SYBX: Forward Price to Sales|Forward P/S Multiple LPCN|Market Cap to Expected Sales Ratio Matinas BioPharma Holdings, Inc.|Price-to-Projected Revenue Ratio Spruce Biosciences Inc. SPRB|GLTO - Forward Price-to-Revenue Multiple|CTCX - Price-to-Projected Revenue Ratio|LUMO - Forward P/S Multiple|ONVO: Forward P/S Multiple|RDUS (Radius Recycling) - Price-to-Projected Revenue Ratio